{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Therese Sørlie"],"instrument_platform":["Illumina NovaSeq X"],"study_type":["RNA-seq of coding RNA"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-17490"],"description":["FGFR1 is upregulated in a proportion of luminal breast cancer. This experiment investigates the role of FGFR1 in activating the cGAS-STING pathway.  Data include RNA sequencing of the tamoxifen-resistant T47D (TR-T47D) cell line after knock down by short hairpin RNA with and without treatment with the synthetic double-stranded DNA polymer poly(dA:dT). Sample set is comprised of 4 treatment groups and 4 replicates of each: ish-control +/- polyd(dA:dT), shFGFR1 +/- polyd(dA:dT)."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Library Construction - mRNA library preparation (poly A enrichment) by Novogene","Sample Collection - RNA extracted from in vitro cell cultures.","Nucleic Acid Extraction - RNA extraction by RNeasy isolation kit by Qiagen.","Sequencing - NovaSeq X Plus Series (PE150) by Novogene","Growth Protocol - TR-T47D shCTRL/shFGFR1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, GlutaMAX™ (2 mM), insulin (8 μg/ml), and maintained in 2 μg/ml puromycin to ensure stable shRNA expression.","Sample Treatment - Stable FGFR1 knockdown and control cells (TR-T47D shFGFR1, TR-T47DshCTRL) were generated by transduction with MISSION® shRNA lentiviral particles targeting FGFR1 (Sigma-Aldrich, Cat. #TRCN0000121185) and MISSION® pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles  (Sigma-Aldrich, Cat. #SHC002V). Cells were transfected with lentiviral particles in Polybrene Infection / Transfection Reagent (Sigma-Aldrich, Cat. #TR-1003) according to the manufacturer's protocol. The cells were selected with 2 μg/mL of puromycin (Sigma-Aldrich, Cat. #P4512) after 48 hours of treatment with lentiviral particles. For Poly(dA:dT) transfections, cells were incubated with 5 µg/ml pre-complexed Poly(dA:dT)/LyoVec™ (InvivoGen, cat. no. tlrl-patc) for 24 h, with H₂O used as the control."],"figure_sub":["Organization","MINSEQE Score","Assays and Data","MAGE-TAB Files"],"pubmed_authors":["Therese Sørlie"],"additional_accession":[]},"is_claimable":false,"name":"RNA sequencing data for knockdown of FGFR1 in TR-T47D cells","description":"FGFR1 is upregulated in a proportion of luminal breast cancer. This experiment investigates the role of FGFR1 in activating the cGAS-STING pathway.  Data include RNA sequencing of the tamoxifen-resistant T47D (TR-T47D) cell line after knock down by short hairpin RNA with and without treatment with the synthetic double-stranded DNA polymer poly(dA:dT). Sample set is comprised of 4 treatment groups and 4 replicates of each: ish-control +/- polyd(dA:dT), shFGFR1 +/- polyd(dA:dT).","dates":{"release":"2026-08-17T00:00:00Z","modification":"2026-08-17T01:00:46.257Z","creation":"2026-08-13T19:36:02.25Z"},"accession":"E-MTAB-17490","cross_references":{"ENA":["ERP203679"],"EFO":["EFO_0002944","EFO_0004170","EFO_0003789","EFO_0005518","EFO_0003738","EFO_0004184","EFO_0003969"]}}